News & Updates

De-escalation of chemotherapy dose and trastuzumab duration may not increase the risk of distant relapse or death in patients with ERBB2-positive (also referred to as HER2-positive) early breast cancer and tumour infiltrating lymphocyte (TIL) levels of ≥20 percent, according to a 10-year analysis of the phase III ShortHER trial.

Paediatric post-COVID syndrome (pPCS) brings a substantial socio-educational burden that must be included in medical, social, and educational care, suggests a study.